Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.

about

Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.

P2860

Q38713191-77270ABB-2665-4183-9212-9DAC63FE2A06

P2860

Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.

Item

http://www.wikidata.org/entity/Q53251508

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Effects of combination treatme ...... drenocortical carcinoma cells.

@en

Effects of combination treatme ...... drenocortical carcinoma cells.

@nl

type

Item

label

Effects of combination treatme ...... drenocortical carcinoma cells.

@en

Effects of combination treatme ...... drenocortical carcinoma cells.

@nl

prefLabel

Effects of combination treatme ...... drenocortical carcinoma cells.

@en

Effects of combination treatme ...... drenocortical carcinoma cells.

@nl

P1476

Effects of combination treatme ...... drenocortical carcinoma cells.

@en

P2093

Leo J Hofland

http://www.w3.org/2001/XMLSchema#string

Maria Cristina De Martino

http://www.w3.org/2001/XMLSchema#string

Peter M van Koetsveld

http://www.w3.org/2001/XMLSchema#string

Richard A Feelders

http://www.w3.org/2001/XMLSchema#string

Steven W J Lamberts

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.

Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Human adrenocortical carcinoma cell lines.

Role of the mTOR pathway in normal and tumoral adrenal cells.

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.

Therapeutic management of advanced adrenocortical carcinoma: what do we know in 2011?

Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors.

Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.

The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.

P2888

s12020-015-0818-0

P304

664-667

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12020-015-0818-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Wouter W de Herder

Rosario Pivonello

Annamaria Colao

P577

2015-12-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26645813

http://www.w3.org/2001/XMLSchema#string

Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.

about

P2860

P2860

Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698